Archive: Company News

Company News: Aleva Neurotherapeutics Recruits First Patient into its PMCF Study with its directSTIM™ Directional Deep Brain Stimulation System

— First system implanted at University Hospital of Dresden / Prof. Sobottka

— Post-market clinical follow-up and revenue-generating study in the EU

— Targeting US FDA IDE approval in Q4, 2021

Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced the successful implantation of a first patient with the directSTIMTM Directional Deep Brain Stimulation System.

Read more…

Science Translational Medicine Publication: Innovative Molecules´ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

— IM-250 reduces viral load, viral shedding and recurrence rate

— Potential treatment for persistent, neurotrophic herpes simplex

Innovative Molecules GmbH, a drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced preclinical data demonstrating that the Company’s drug candidate IM-250 affects acute as well as chronic neural Herpes simplex virus (HSV) infections in mice and guinea pigs. IM-250 is a proprietary, novel helicase-primase inhibitor.

Read more…

Company News: Innovative Molecules raises €20 million Series A equity financing round

— Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II

— IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies

Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its €20 million Series A equity financing round led by LSP (Life Sciences Partners).

Read more…

Company News: Patients with Risk Factors Benefit from Using COPAL® G+C from Heraeus Medical in Arthroplasty Procedures

– New studies reveal benefits of dual antibiotic-loaded bone cement (COPAL® G+C) to reduce periprosthetic joint infections in risk for infection patients

– 34% reduction of infection risk for primary procedures

– 57% reduction of infection risk for aseptic knee revisions

Patients at risk of infection benefit from bone cement with a combination of antibiotics

COPAL® G+C bone cement containing two antibiotics has long been used for revisions after replacement of hip or knee joints.

Read more…

1 2 132